Pfizer has announced that it will not launch its Amsparity (adalimumab) biosimilar in Europe, just weeks after the rival to Humira received a formal endorsement from the European Medicines Agency’s Committee for Medicinal Products for Human Use, recommending granting a pan-European marketing authorization.
The CHMP nod puts Amsparity in line for an imminent approval from the European Commission, which is responsible for issuing...